New obesity drug from Lilly delivers major weight loss
Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients lose 28.3 percent of their weight from baseline— or 70.3 pounds — on average over 80 weeks, compared with 2.2 percent with placebo. The results evaluated only the patients who stayed on the drug.
- ▪Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss.
- ▪The highest dose of retatrutide helped patients lose 28.3 percent of their weight from baseline— or 70.3 pounds — on average over 80 weeks, compared with 2.2 percent with placebo.
- ▪The results evaluated only the patients who stayed on the drug.
Opening excerpt (first ~120 words) tap to expand
Healthcare New obesity drug from Lilly delivers major weight loss Comments: by Nathaniel Weixel - 05/21/26 3:04 PM ET Comments: Link copied by Nathaniel Weixel - 05/21/26 3:04 PM ET Comments: Link copied NOW PLAYING An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients lose 28.3 percent of their weight from baseline— or 70.3 pounds — on average over 80 weeks, compared with 2.2 percent with placebo.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hill.
Discussion
0 commentsMore from The Hill
